Multivax P

Indications

• Vaccination against infectious diseases
• Diagnosis of allergies
• Cancer immunotherapy
• Autoimmune disease modulation

Dosage

Children: Refer to specific product guidelines as doses can vary based on the antigen and the purpose of administration.

Adults: Refer to specific product guidelines as doses can vary based on the antigen and the purpose of administration.

Mechanism of action

Antigens act by binding to specific receptors on immune cells, such as B cells and T cells. This binding activates these cells, leading to the production of antibodies (in the case of B cells) or cytotoxic responses (in the case of T cells). The recognition of antigens by the immune system involves antigen presentation by Major Histocompatibility Complex (MHC) molecules, which display peptide fragments of the antigen on the surface of antigen-presenting cells.

Pharmacodynamics

The presence of antigens triggers a series of immune responses, including the activation of lymphocytes, cytokine production, and the formation of memory cells. These processes are essential for the body to recognize and mount an effective defense against subsequent exposures to the same antigen, contributing to immunological memory and long-term protection.

Pharmacokinetics

The pharmacokinetics of antigens can vary widely depending on their nature and route of administration. Generally, antigens can be administered via intramuscular, subcutaneous, or intradermal routes. Upon administration, they are processed by antigen-presenting cells, which then migrate to lymph nodes to activate T and B cells. The distribution, metabolism, and elimination of antigens depend on their structure and the immune response they elicit.

Adverse effects

• Local reactions at the injection site
• Systemic allergic reactions
• Fever
• Fatigue
• Headache
• Nausea

Precautions

• Monitor for allergic reactions after administration
• Use with caution in individuals with a history of severe allergic reactions
• Consider the patient's immune status before administration

Pregnancy

Consult a healthcare professional before use. The safety of antigens in pregnancy varies depending on the type of antigen and the specific clinical context.

Breast-feeding

Consult a healthcare professional before use. The transfer of antigens into breast milk is variable and depends on the type of antigen.

Storage

Store at recommended temperatures, usually between 2°C and 8°C. Protect from light and do not freeze.

Formulations

• Injectable solutions
• Suspensions
• Lyophilized powders for reconstitution

Indications

• Prevention of blackleg in cattle
• Prevention of blackleg in sheep

Dosage

Children: Refer to veterinary guidelines for specific dosing recommendations, as doses can vary based on the formulation and route of administration.

Adults: Refer to veterinary guidelines for specific dosing recommendations, as doses can vary based on the formulation and route of administration.

Mechanism of action

Clostridium chauvoei produces a range of toxins, including alpha-toxin, which is a phospholipase that damages host cell membranes, leading to cell lysis and tissue necrosis. The toxins disrupt normal cellular function and promote inflammation, contributing to the clinical manifestations of the disease.

Pharmacodynamics

The primary pharmacodynamic action of Chauvoei is the induction of necrotizing myositis and systemic toxicity through the production of its virulence factors. The release of toxins into the bloodstream can cause fever, shock, and, in severe cases, death. The disease is characterized by sudden onset, rapid progression, and a high mortality rate if not treated promptly.

Pharmacokinetics

The pharmacokinetics of Chauvoei are not typically studied in the same manner as traditional pharmaceuticals, given that it is a bacterium rather than a medication. However, once the spores are introduced into the host, they germinate in anaerobic conditions, multiply rapidly, and produce toxins, resulting in the clinical disease. The immune response may help to clear the infection, but in severe cases, the disease progresses rapidly, necessitating immediate veterinary intervention.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering to breastfeeding mothers, as safety is not established.

Storage

Store in a cool, dry place away from light. Protect from freezing.

Formulations

• Injectable solution

Indications

• Botulism
• Tetanus
• Clostridium difficile infection
• Pseudomembranous colitis

Dosage

Adults: Refer to specific clinical guidelines for dosage based on the condition being treated, as Clostridium infections require targeted therapies and may involve antitoxins, antibiotics, or supportive

Mechanism of action

Clostridium species produce potent exotoxins that interfere with normal cellular functions. For instance, Clostridium botulinum produces botulinum toxin, which inhibits acetylcholine release at the neuromuscular junction, leading to paralysis. Clostridium tetani produces tetanospasmin, which blocks inhibitory neurotransmitter release in the central nervous system, resulting in muscle spasms. Clostridium difficile releases toxins A and B, which disrupt the intestinal epithelium and cause inflammation, leading to diarrhea.

Pharmacodynamics

The pharmacodynamic effects of Clostridium toxins are primarily driven by their enzymatic activities. Botulinum toxin is the most potent toxin known and acts at neuromuscular junctions, causing flaccid paralysis. Tetanospasmin affects central nervous system neurotransmission, leading to spastic paralysis. Toxins produced by Clostridium difficile lead to cell death and inflammatory responses in the colon, contributing to pseudomembranous colitis.

Pharmacokinetics

The pharmacokinetics of Clostridium infections vary by species and toxin type. Generally, the toxins are absorbed into circulation following local release at infection sites. For example, botulinum toxin is absorbed through the gastrointestinal tract when ingested and distributed throughout the body, while tetanospasmin acts locally and is transported retrograde along motor neurons to the central nervous system. The duration of action is influenced by the toxin's ability to bind to receptors and enter cells, as well as the body's capacity for toxin clearance.

Pregnancy

The safety of clostridium species during pregnancy has not been established. Caution is advised when administering to pregnant individuals.

Breast-feeding

The effects of clostridium species during breastfeeding are not well studied. Caution is recommended.

Storage

Store in a cool, dry place away from direct sunlight. Specific storage conditions may vary based on formulation.

Indications

• Bacterial meningitis
• Pneumonia
• Epiglottitis
• Otitis media
• Sinusitis
• Sepsis

Dosage

Children: Refer to the BNF for Children for age-appropriate dosing guidelines based on the specific antibiotic and clinical scenario.

Adults: Refer to specific antibiotic guidelines based on culture and sensitivity results, as well as the severity of the infection.

Mechanism of action

The mechanism of action of antibiotics used to treat infections caused by haemolytica involves inhibition of bacterial cell wall synthesis, protein synthesis, or nucleic acid synthesis, depending on the specific antibiotic. For instance, beta-lactam antibiotics target penicillin-binding proteins, disrupting cell wall formation, leading to cell death.

Pharmacodynamics

Pharmacodynamics of antibiotics against haemolytica involves their ability to inhibit bacterial growth (bacteriostatic) or kill bacteria (bactericidal), depending on the drug class. The efficacy of these agents is often evaluated based on their minimum inhibitory concentration (MIC) and their ability to achieve therapeutic concentrations at the site of infection.

Pharmacokinetics

Pharmacokinetics of antibiotics vary widely but generally encompass absorption, distribution, metabolism, and excretion (ADME) profiles. Many antibiotics are rapidly absorbed in the gastrointestinal tract, distributed widely in body tissues, and are excreted primarily via the kidneys. Half-lives can vary significantly, influencing dosing frequency.

Pregnancy

There is limited data on the use of haemolytica in pregnancy. Caution is advised, and it should be used only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

There is insufficient information regarding the safety of haemolytica during breastfeeding. Caution is recommended.

Storage

Store in a cool, dry place away from direct sunlight. Ensure it is kept out of reach of children.

Indications

• Influenza prevention
• Hepatitis A prevention
• Rabies prophylaxis
• Polio prevention
• Typhoid fever prevention

Dosage

Children: Refer to specific vaccine guidelines for paediatric dosing, as it varies depending on the vaccine type and indication.

Adults: Refer to specific vaccine guidelines for adult dosing, as it varies depending on the vaccine type and indication.

Mechanism of action

Killed vaccines work by presenting inactivated pathogens or their components (antigens) to the immune system. This exposure prompts the immune system to produce antibodies and memory cells, preparing the body to respond to future infections by the live version of the pathogen. The inactivation process ensures that the vaccine is safe and cannot cause disease.

Pharmacodynamics

The pharmacodynamics of killed vaccines involve the activation of the immune system, specifically the adaptive immune response. Upon administration, the immune system recognizes the inactivated antigens as foreign, leading to the activation of T-cells and B-cells. B-cells produce antibodies against the specific pathogen, which can remain in the body for a prolonged period, providing immunity against future infections. The response may vary based on the individual and the specific vaccine used.

Pharmacokinetics

Killed vaccines do not undergo metabolism in the traditional sense as they are not pharmacological agents that exert effects systemically. Instead, they are processed through the immune system. After administration, the inactivated pathogens are taken up by antigen-presenting cells, which process the antigens and present them to T-cells. The immune response can take days to weeks to develop fully. The duration of immunity may vary depending on the vaccine and the individual's immune response.

Pregnancy

Consult healthcare provider. Safety during pregnancy has not been established.

Breast-feeding

Consult healthcare provider. Safety during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Cellulitis
• Abscess formation
• Respiratory tract infections
• Septic arthritis
• Osteomyelitis
• Systemic infections following animal bites

Dosage

Children: Refer to specific antibiotic guidelines for dosing based on the type and severity of infection.

Adults: Refer to specific antibiotic guidelines for dosing based on the type and severity of infection.

Mechanism of action

Pasteurella multocida can cause disease by evading host immune responses and producing virulence factors like polysaccharide capsules, endotoxins, and enzymes that disrupt host cell functions. These mechanisms enable the bacteria to adhere to host tissues, invade cells, and evade phagocytosis, contributing to its pathogenicity.

Pharmacodynamics

The pharmacodynamics of Pasteurella infections largely depend on the host's immune response and the antibiotics used for treatment. Pasteurella multocida is typically susceptible to a range of antibiotics, including beta-lactams, tetracyclines, and macrolides, but resistance can occur. Effective management of infections usually requires timely antibiotic therapy, particularly in cases of severe or systemic infection.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat Pasteurella infections varies by drug. Generally, these antibiotics are absorbed through the gastrointestinal tract, distributed widely in body tissues, and excreted primarily via renal pathways. The choice of antibiotic and its dosing regimen will depend on the severity of the infection, the patient's renal function, and the specific antibiotic used.

Pregnancy

There are no well-controlled studies in pregnant women. Use only if clearly needed.

Breast-feeding

Caution should be exercised when administered to a nursing mother.

Storage

Store at room temperature, away from moisture and heat.

Indications

• Gas gangrene
• Clostridial myonecrosis
• Food poisoning
• Soft tissue infections

Dosage

Children: Refer to specific antibiotic guidelines for dosing as it varies by drug choice and severity of the infection.

Adults: Refer to specific antibiotic guidelines for dosing as it varies by drug choice and severity of the infection.

Mechanism of action

Clostridium perfringens produces several toxins, including alpha-toxin (lecithinase), which disrupts cell membranes and promotes tissue destruction. The toxins act on phospholipids in cell membranes, leading to cell lysis and necrosis. Additionally, the bacterium's ability to produce gas (hydrogen and carbon dioxide) contributes to tissue swelling and further compromises blood flow.

Pharmacodynamics

The pharmacodynamics of antibiotics used against Clostridium perfringens involve the inhibition of bacterial cell wall synthesis (for beta-lactams), disruption of protein synthesis (for aminoglycosides and tetracyclines), or interference with nucleic acid synthesis (for fluoroquinolones). The effectiveness of these antibiotics can vary based on the specific strain and its susceptibility profile.

Pharmacokinetics

Pharmacokinetic properties depend on the specific antibiotic used to treat Clostridium perfringens infections. Generally, antibiotics may have varying absorption rates, distribution volumes, half-lives, and elimination routes, which can influence their dosing and effectiveness in treating infections caused by this organism.

Pregnancy

Perfringens is not typically used as a medication but is related to Clostridium perfringens, which is associated with foodborne illness. Consult healthcare providers for guidance during pregnancy.

Breast-feeding

Due to the lack of specific medicinal use, consult healthcare providers for advice regarding breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. If used in a laboratory context, follow specific biosafety guidelines.

Dosage

Children: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Adults: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Mechanism of action

The mechanism of action for purified compounds varies widely depending on the specific substance. Generally, purified drugs exert their effects by interacting with specific biological targets, such as receptors, enzymes, or ion channels, leading to a desired therapeutic effect. This interaction can involve binding to receptors to activate or inhibit signaling pathways, modulating enzymatic activity, or altering physiological processes.

Pharmacodynamics

Pharmacodynamics describes the effects of a drug on the body and the relationship between drug concentration and effect. For purified drugs, this can involve dose-response relationships and the time course of their action. The purified form often enhances potency and reduces variability in response among patients, which can lead to more predictable therapeutic outcomes. The overall effect is determined by the drug's affinity for its target, the efficacy of the drug-receptor interaction, and the downstream signaling pathways activated as a result of this interaction.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of a drug. For purified substances, absorption can be more efficient due to the absence of impurities that may affect solubility or stability. Distribution may also be enhanced, leading to higher bioavailability. Metabolism can be influenced by the structure of the purified compound, as it may be metabolized more readily by liver enzymes. Excretion typically occurs through the kidneys or liver, depending on the molecular characteristics of the purified drug.

Pregnancy

Consult with a healthcare professional, as the safety of purified forms of medications during pregnancy may vary depending on the specific substance.

Breast-feeding

Consult with a healthcare professional, as the safety of purified forms of medications during breastfeeding may vary depending on the specific substance.

Storage

Store in a cool, dry place, away from light and moisture, and keep out of reach of children.

Indications

• Bacterial infections
• Pneumonia
• Skin and soft tissue infections
• Urinary tract infections
• Bone and joint infections

Dosage

Children: Dosing for paediatric patients should be determined based on age, weight, and specific clinical guidelines. Refer to appropriate pediatric dosing references for detailed guidance.

Adults: Dosage varies based on the type and severity of infection. Refer to established clinical guidelines for specific dosing regimens.

Mechanism of action

Septicum works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. It binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, disrupting the cross-linking of peptidoglycan layers, which is essential for bacterial cell wall structural integrity.

Pharmacodynamics

The pharmacodynamics of Septicum involve the relationship between its concentration and the effect on bacterial growth and survival. It exhibits time-dependent killing, meaning that its efficacy is related to the duration of time that the drug concentration remains above the minimum inhibitory concentration (MIC) for the target organism. Bacterial resistance can develop, particularly with prolonged use or in immunocompromised patients.

Pharmacokinetics

Septicum is absorbed well from the gastrointestinal tract, with peak plasma concentrations occurring within 1 to 2 hours after oral administration. It is widely distributed throughout body tissues and fluids, with a volume of distribution that suggests extensive tissue penetration. The drug is primarily excreted unchanged in the urine, and its half-life is approximately 1 to 2 hours in individuals with normal renal function. Dosing adjustments may be necessary in patients with renal impairment.

Pregnancy

The effects of septicum during pregnancy are not well studied. It should be used only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unknown whether septicum is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Infection diagnosis
• Vaccine development
• Epidemiological studies
• Immunology research

Dosage

Children: Refer to specific guidelines based on the serotype and associated treatment or vaccine.

Adults: Refer to specific guidelines based on the serotype and associated treatment or vaccine.

Mechanism of action

Serotypes exhibit differences in their surface antigens, which can include polysaccharides, proteins, or lipopolysaccharides. These variations affect how the immune system recognizes and responds to the pathogen. For example, certain serotypes may evade immune detection or induce a stronger immune response, influencing both disease severity and immunization strategies.

Pharmacodynamics

The pharmacodynamics of serotypes primarily involves their interaction with the immune system. The specific antigens present on the surface of a serotype determine its immunogenicity, influencing how well the immune system can recognize and mount a response against it. This can result in varied clinical outcomes, ranging from asymptomatic carriage to severe disease.

Pharmacokinetics

The pharmacokinetics of serotypes is not directly applicable as serotypes themselves are not drugs, but rather classifications of microorganisms. However, understanding the distribution, metabolism, and excretion of the pathogens associated with different serotypes can provide insights into infection dynamics and treatment responses.

Pregnancy

Safety during pregnancy has not been established for all serotypes. Consult healthcare providers for specific risks.

Breast-feeding

Consult healthcare providers regarding the safety of specific serotypes during breastfeeding.

Storage

Store according to specific guidelines for each serotype, typically in a cool, dry place away from direct sunlight.

Indications

• Tetanus prophylaxis in unimmunized individuals
• Management of active tetanus infection
• Prevention of tetanus in surgical procedures

Dosage

Adults: Refer to specific guidelines for tetanus immunization and management of active

Mechanism of action

The primary mechanism of action of tetanospasmin, the toxin produced by Clostridium tetani, involves the inhibition of neurotransmitter release at inhibitory synapses in the central nervous system. It prevents the release of glycine and gamma-aminobutyric acid (GABA), neurotransmitters that are crucial for muscle relaxation. This leads to unopposed excitation of motor neurons, resulting in the characteristic muscle spasms and rigidity associated with tetanus.

Pharmacodynamics

The pharmacodynamics of tetanospasmin involve its interaction with the nervous system, particularly at the spinal cord level. Once the toxin enters the bloodstream and binds to peripheral nerves, it retrogradely transports to the spinal cord, where it interferes with inhibitory pathways. This disruption leads to hyperexcitability of motor neurons, causing sustained muscle contractions and spasms. The severity of symptoms can vary based on the amount of toxin produced and the individual's immune response.

Pharmacokinetics

The pharmacokinetics of the tetanospasmin toxin are complex, as it is not a conventional drug with defined pharmacokinetic parameters. After release into the body, the toxin binds rapidly to nerve endings and is taken up into motor neurons. The onset of symptoms typically occurs within 7 to 14 days after infection, although it can vary. The half-life of the toxin is not well-defined due to its irreversible binding properties and the body's subsequent immune response to the toxin. The duration of the clinical effects can last from several days to weeks, depending on the severity of the infection and the treatment administered.

Pregnancy

There is limited data on the use of tetani during pregnancy. Consult clinical guidelines and consider risk versus benefit.

Breast-feeding

Consult clinical guidelines. Use with caution and consider risk versus benefit when breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Follow specific storage instructions as per the manufacturer's guidelines.

Dosage

Children: Refer to specific drug guidelines as dosing in units varies based on the drug and its clinical application.

Adults: Refer to specific drug guidelines as dosing in units varies based on the drug and its clinical application.

Mechanism of action

The mechanism of action of drugs measured in units depends on the specific substance. For example, insulin (measured in units) facilitates glucose uptake in cells by binding to insulin receptors, activating a signaling pathway that enhances glucose transporter translocation to the cell membrane. This results in a decrease in blood glucose levels. Similarly, other drugs measured in units may exert their effects through receptor binding, enzyme catalysis, or other biochemical interactions.

Pharmacodynamics

Pharmacodynamics describes the effects of the drug on the body and includes the relationship between drug concentration and effect. For substances measured in units, the pharmacodynamic response may be variable and is often dependent on the individual’s sensitivity to the drug, receptor availability, and other pharmacological factors. For instance, the effect of 1 unit of insulin can vary significantly among individuals based on their insulin sensitivity and metabolic state.

Pharmacokinetics

Pharmacokinetics refers to the absorption, distribution, metabolism, and excretion of drugs. For substances measured in units, the pharmacokinetic profile can differ widely. For instance, insulin is rapidly absorbed when administered subcutaneously, distributed throughout the body, metabolized by the liver and kidneys, and its effects can be observed within minutes. Other drugs may have different absorption rates, half-lives, and routes of elimination.

Pregnancy

Consult a healthcare professional. The safety of this drug during pregnancy has not been established.

Breast-feeding

Consult a healthcare professional. The safety of this drug during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Mechanism of action

... Chemicals such as tetranitromethane ... generate tumors with mutations consistent with the result of DNA adduct formation ... Tetranitromethane treatment of 3-ketosteroid-Delta(1)-dehydrogenase of Rhodococcus rhodochrous caused loss of the catalytic activity in a time- and concentration-dependent manner. Peptides (P-81) and (PN-83) were isolated from tryptic digests of the native and tetranitromethane-treated enzyme proteins, respectively. PN-83 was the nitrated form of P-81. The amino acid sequence was GGAPLIDYLESDDDLEFMVYPWPDYFGK (positions 97-124 of the dehydrogenase sequence). PN-83 showed a low yield of PTH-Tyr of position 116, i.e. less than 5% of that of P-81, and instead a high yield of PTH-3-nitrotyrosine. This indicated that tetranitromethane modifies Y-116 under the experimental conditions used. Mutation of Y-104, Y-116, and Y-121 to smaller amino acid residues, Phe, Ser, or Ala, significantly changed the catalytic activity of the dehydrogenase. All of the mutants contained FAD and exhibited the same spectrophotometric properties as those of the wild type enzyme. The K(m) values for 4-androstene-3,17-dione of the Y-104, Y-116, and Y-121 mutants changed to large values. The most drastic change was observed for Y116A. The K(d) values for 1,4-androstadiene-3,17-dione of the Y116 mutants changed to 1.5-2.6-fold larger values than that of the recombinant enzyme. The Y-121 mutant enzymes exhibited catalytic activities like those of the recombinant enzyme, but the catalytic efficiencies of Y121F and Y121A drastically decreased to 0. 014-0.054% of that of the recombinant enzyme. The present results indicate that Y-121 plays an important role in the catalytic function, and that Y-116 and Y-104 act on binding of the substrate steroid.